MCID: GLL017
MIFTS: 43

Gallbladder Adenocarcinoma

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Gallbladder Adenocarcinoma

MalaCards integrated aliases for Gallbladder Adenocarcinoma:

Name: Gallbladder Adenocarcinoma 12 15 17 71
Adenocarcinoma of the Gallbladder 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3500
NCIt 49 C9166
UMLS 71 C0279651

Summaries for Gallbladder Adenocarcinoma

Disease Ontology : 12 A gallbladder carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Gallbladder Adenocarcinoma, also known as adenocarcinoma of the gallbladder, is related to gallbladder cancer and in situ carcinoma, and has symptoms including abdominal pain An important gene associated with Gallbladder Adenocarcinoma is ERBB2 (Erb-B2 Receptor Tyrosine Kinase 2), and among its related pathways/superpathways are Endometrial cancer and Downstream signaling events of B Cell Receptor (BCR). The drugs Oxaliplatin and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include breast, lung and liver, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Gallbladder Adenocarcinoma

Diseases related to Gallbladder Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 221)
# Related Disease Score Top Affiliating Genes
1 gallbladder cancer 31.0 TP53 PSCA PIK3CA ERBB2 EGFR
2 in situ carcinoma 30.6 TP53 ERBB2 EGFR
3 adenocarcinoma 30.6 TP53 PIK3CA KRT20 ERBB2 EPHA7 EGFR
4 large cell neuroendocrine carcinoma 30.3 KRT20 ERBB2 EGFR
5 adenosquamous carcinoma 30.3 TP53 PIK3CA EGFR
6 carcinosarcoma 30.1 TP53 PIK3CA ERBB2 EGFR
7 gallbladder disease 30.0 TP53 ERBB2 EGFR
8 small cell carcinoma 30.0 TP53 KRT20 EGFR
9 clear cell adenocarcinoma 29.9 TP53 PIK3CA KRT20
10 mucinous adenocarcinoma 29.9 TP53 KRT20 ERBB2 EGFR
11 tubular adenocarcinoma 29.8 KRT20 ERBB2 EGFR
12 bile duct cancer 29.6 TP53 KRT20 ERBB2 EGFR
13 cholangiocarcinoma 29.4 TP53 PIK3CA KRT20 ERBB2 EGFR
14 pancreatic ductal adenocarcinoma 29.4 TP53 PROM1 ERBB2 EGFR
15 signet ring cell adenocarcinoma 29.3 TP53 SRC KRT20 ERBB2
16 leukemia, chronic lymphocytic 29.1 TP53 SRC PEG10 ERBB2 EGFR
17 intrahepatic cholangiocarcinoma 28.7 TP53 PROM1 KRT20 ERBB2 EGFR
18 bladder cancer 28.2 TP53 SRC PSCA PIK3CA KRT20 ERBB2
19 gastric adenocarcinoma 28.1 TP53 PSCA PROM1 PIK3CA KRT20 ERBB2
20 adenocarcinoma of the gallbladder and extrahepatic biliary tract 12.5
21 gallbladder pleomorphic giant cell adenocarcinoma 11.4
22 rare head and neck tumor 10.6 TP53 PIK3CA
23 gastric papillary adenocarcinoma 10.5 TP53 ERBB2
24 rare adenocarcinoma of the breast 10.5 TP53 PIK3CA
25 esophageal basaloid squamous cell carcinoma 10.5 TP53 EGFR
26 esophagus verrucous carcinoma 10.5 TP53 EGFR
27 recurrent respiratory papillomatosis 10.5 ERBB2 EGFR
28 breast scirrhous carcinoma 10.5 ERBB2 EGFR
29 apocrine adenosis of breast 10.5 TP53 ERBB2
30 parotid gland cancer 10.5 TP53 ERBB2
31 comedo carcinoma 10.5 TP53 ERBB2
32 frontal lobe neoplasm 10.5 TP53 EGFR
33 pleomorphic adenoma carcinoma 10.5 TP53 ERBB2
34 breast metaplastic carcinoma 10.5 ERBB2 EGFR
35 cholecystitis 10.4
36 soft tissue sarcoma 10.4 TP53 EGFR
37 breast squamous cell carcinoma 10.4 TP53 PIK3CA ERBB2
38 cystadenocarcinoma 10.4 TP53 PIK3CA ERBB2
39 breast sarcoma 10.4 TP53 PIK3CA ERBB2
40 ovarian carcinosarcoma 10.4 TP53 PIK3CA ERBB2
41 uterine corpus serous adenocarcinoma 10.4 TP53 PIK3CA ERBB2
42 hypertrophy of breast 10.4 TP53 PIK3CA ERBB2
43 female reproductive endometrioid cancer 10.4 TP53 PIK3CA ERBB2
44 breast malignant phyllodes tumor 10.4 TP53 ERBB2 EGFR
45 serous cystadenocarcinoma 10.4 TP53 PIK3CA ERBB2
46 primary peritoneal carcinoma 10.4 TP53 ERBB2 EGFR
47 anus cancer 10.4 TP53 PIK3CA EGFR
48 microglandular adenosis 10.4 TP53 ERBB2 EGFR
49 peritoneum cancer 10.4 TP53 ERBB2 EGFR
50 large intestine adenocarcinoma 10.4 TP53 ERBB2

Graphical network of the top 20 diseases related to Gallbladder Adenocarcinoma:



Diseases related to Gallbladder Adenocarcinoma

Symptoms & Phenotypes for Gallbladder Adenocarcinoma

UMLS symptoms related to Gallbladder Adenocarcinoma:


abdominal pain

GenomeRNAi Phenotypes related to Gallbladder Adenocarcinoma according to GeneCards Suite gene sharing:

26 (show all 27)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-118 9.78 EGFR
2 Increased shRNA abundance (Z-score > 2) GR00366-A-12 9.78 TP53
3 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.78 TP53
4 Increased shRNA abundance (Z-score > 2) GR00366-A-121 9.78 EGFR
5 Increased shRNA abundance (Z-score > 2) GR00366-A-132 9.78 ERP29 TP53
6 Increased shRNA abundance (Z-score > 2) GR00366-A-147 9.78 ERP29
7 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.78 PIK3CA
8 Increased shRNA abundance (Z-score > 2) GR00366-A-16 9.78 PIK3CA
9 Increased shRNA abundance (Z-score > 2) GR00366-A-166 9.78 PIK3CA
10 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.78 TP53
11 Increased shRNA abundance (Z-score > 2) GR00366-A-173 9.78 ERP29
12 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.78 PIK3CA
13 Increased shRNA abundance (Z-score > 2) GR00366-A-19 9.78 TP53
14 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.78 EGFR ERP29 PIK3CA TP53
15 Increased shRNA abundance (Z-score > 2) GR00366-A-197 9.78 ERP29
16 Increased shRNA abundance (Z-score > 2) GR00366-A-21 9.78 EGFR
17 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.78 EGFR
18 Increased shRNA abundance (Z-score > 2) GR00366-A-35 9.78 TP53
19 Increased shRNA abundance (Z-score > 2) GR00366-A-37 9.78 ERP29
20 Increased shRNA abundance (Z-score > 2) GR00366-A-39 9.78 TP53
21 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.78 PIK3CA
22 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.78 EGFR
23 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.78 PIK3CA
24 Increased shRNA abundance (Z-score > 2) GR00366-A-60 9.78 PIK3CA
25 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.78 EGFR
26 Decreased viability with paclitaxel GR00179-A-1 9.26 EGFR ERBB2 SRC
27 Decreased viability with paclitaxel GR00179-A-3 9.26 EGFR

MGI Mouse Phenotypes related to Gallbladder Adenocarcinoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.96 CD82 EGFR ERBB2 MCAM MSI1 MTDH
2 integument MP:0010771 9.76 EGFR ERBB2 MTDH PIK3CA PSCA SRC
3 neoplasm MP:0002006 9.65 CD82 EGFR ERBB2 MTDH PIK3CA PROM1
4 normal MP:0002873 9.23 EGFR ERBB2 MSI1 MTDH PROM1 PSCA

Drugs & Therapeutics for Gallbladder Adenocarcinoma

Drugs for Gallbladder Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 35)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 5310940 9887054 6857599 43805
2
Cisplatin Approved Phase 2, Phase 3 15663-27-1 84093 441203 2767
3
Gemcitabine Approved Phase 3 95058-81-4 60750
4
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
5 Immunologic Factors Phase 3
6 Anti-Infective Agents Phase 3
7 Antiviral Agents Phase 3
8 Immunosuppressive Agents Phase 3
9 Antimetabolites Phase 3
10 Liver Extracts Phase 3
11
Bevacizumab Approved, Investigational Phase 2 216974-75-3
12
Melphalan Approved Phase 2 148-82-3 4053 460612
13
Pancrelipase Approved, Investigational Phase 2 53608-75-6
14
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
15
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
16 Pancreatic Polypeptide Investigational Phase 2 59763-91-6
17 Angiogenesis Inhibitors Phase 2
18 Antineoplastic Agents, Immunological Phase 2
19 Alkylating Agents Phase 2
20 pancreatin Phase 2
21 Vaccines Phase 2
22 Adjuvants, Immunologic Phase 2
23 Freund's Adjuvant Phase 2
24 Cola Phase 2
25
Metronidazole Approved Phase 1 443-48-1 4173
26
Atezolizumab Approved, Investigational Phase 1 1380723-44-3
27 Protein Kinase Inhibitors Phase 1
28
Erlotinib Hydrochloride Phase 1 183319-69-9 176871
29 Antiparasitic Agents Phase 1
30 Antiprotozoal Agents Phase 1
31 Anti-Bacterial Agents Phase 1
32 Gastrointestinal Agents Phase 1
33 Antibodies, Monoclonal Phase 1
34 Immunoglobulins Phase 1
35 Antibodies Phase 1

Interventional clinical trials:

(show all 20)
# Name Status NCT ID Phase Drugs
1 A Randomised Clinical Trial Evaluating Adjuvant Chemotherapy With Capecitabine Compared to Expectant Treatment Alone (Observation) Following Surgery for Biliary Tract Cancer Completed NCT00363584 Phase 3 capecitabine
2 Phase III Multicenter Randomized Study Comparing the Effect of Adjuvant Chemotherapy for Six Months With Gemcitabine-Oxaliplatin 85 mg/m2 (GEMOX 85) to Observation in Patients Who Underwent Surgery for Cancer of the Bile Ducts Completed NCT01313377 Phase 3 gemcitabine hydrochloride;oxaliplatin
3 Perioperative Therapy Preoperative Chemotherapy Versus Chemoradiotherapy in Locally Advanced Gall Bladder Cancers Recruiting NCT02867865 Phase 2, Phase 3 Gemcitabine;Cisplatin
4 A Phase III Study of Gemcitabine Plus Capecitabine (GEMCAP) Versus Gemcitabine Alone in Advanced Biliary Cancer Terminated NCT00658593 Phase 3 capecitabine;gemcitabine hydrochloride
5 A Multicenter Phase II Study of Gemcitabine, Capecitabine and Bevacizumab for Locally Advanced or Metastatic Adenocarcinoma of the Gall Bladder or Biliary Ducts. Completed NCT01007552 Phase 2 Gemcitabine, Capecitabine and Bevacizumab
6 A Phase II Trial of Gemcitabine (NSC-613327) and Capecitabine (NSC-712807) in Patients With Unresectable or Metastatic Gallbladder or Cholangiocarcinoma Completed NCT00033540 Phase 2 capecitabine;gemcitabine hydrochloride
7 Capecitabine And Gemcitabine In Patients With Advanced Or Metastatic Biliary Tract Cancer, A Multicenter Phase II Trial Completed NCT00073905 Phase 2 capecitabine plus gemcitabine
8 A Phase II Study Of Hepatic Arterial Infusion Of Melphalan With Venous Filtration Via Peripheral Hepatic Perfusion (PHP) For Unresectable Primary And Metastatic Cancers Of The Liver Completed NCT00096083 Phase 2 isolated perfusion;melphalan
9 Phase II Study of Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Biliary Tract and Gallbladder Cancer Completed NCT00142480 Phase 2 Capecitabine;Oxaliplatin;Bevacizumab
10 A Trial Of Vaccination With The Carcinoembryonic Antigen (CEA) Peptide Cap 1-6D With Montanide ISA 51 Adjuvant Or Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) In HLA-A2+ Patients With CEA Producing Adenocarcinomas Of Gastrointestinal (GI) Tract Origin Terminated NCT00012246 Phase 2
11 Phase II and Pharmacodynamic Study of PS-341 in Patients With Unresectable or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder Terminated NCT00085410 Phase 2 bortezomib
12 A Multicenter Phase II Study of the Combination of AZD6244 Hydrogen Sulfate and MK-2206 in Patients With Refractory Advanced Biliary Cancers Withdrawn NCT01859182 Phase 2 selumetinib;Akt inhibitor MK2206
13 Pilot Study of Gemcitabine and IORT/EBRT in Locally Advanced Upper Gastrointestinal Malignancies Completed NCT00544193 Phase 1 gemcitabine hydrochloride
14 A Two-Part Phase I Study of the Addition of Oxaliplatin to Gemcitabine, and Then Erlotinib Plus Oxaliplatin to Gemcitabine as Radiosensitizers for Pancreatic and Biliary Adenocarcinoma Completed NCT00266097 Phase 1 erlotinib hydrochloride;gemcitabine hydrochloride;oxaliplatin;gemcitabine hydrochloride;Oxaliplatin
15 A Phase I Study Of Active Immunotherapy With Autologous Dendritic Cells Infected With CEA-6D Expressing Fowlpox -Tricom In Patients With Advanced Or Metastatic Malignancies Expressing CEA Completed NCT00027534 Phase 1
16 A Phase I, Multi-Dose Study of RAV12 (ANTI-RAAG12 MAB) in Patients With Metastatic or Recurrent Adenocarcinoma Completed NCT00101972 Phase 1
17 Phase I Study of T Cells Modified With Chimeric AntiCEA Immunoglobulin-T Cell Receptors (IgTCR) in Adenocarcinoma Completed NCT00004178 Phase 1
18 Phase Ib Trial of Gemcitabine and Oxaliplatin (GEMOX) With Erlotinib in Patients With Advanced Biliary Tract Cancer. Completed NCT00987766 Phase 1 erlotinib hydrochloride;gemcitabine hydrochloride;oxaliplatin
19 A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma Terminated NCT03267940 Phase 1 PEGPH20;CIS;GEM;Atezolizumab
20 Visceral Lymphatic Mapping Project: A Pilot Study Completed NCT00489515

Search NIH Clinical Center for Gallbladder Adenocarcinoma

Genetic Tests for Gallbladder Adenocarcinoma

Anatomical Context for Gallbladder Adenocarcinoma

MalaCards organs/tissues related to Gallbladder Adenocarcinoma:

40
Breast, Lung, Liver, T Cells, Lymph Node, Brain, Colon

Publications for Gallbladder Adenocarcinoma

Articles related to Gallbladder Adenocarcinoma:

(show top 50) (show all 441)
# Title Authors PMID Year
1
Germline alterations in patients with biliary tract cancers: A spectrum of significant and previously underappreciated findings. 61
32012241 2020
2
Anti-diabetic drug metformin inhibits cell proliferation and tumor growth in gallbladder cancer via G0/G1 cell cycle arrest. 61
31815765 2019
3
Systematic Selective Sampling of Cholecystectomy Specimens Is Adequate to Detect Incidental Gallbladder Adenocarcinoma. 61
31464710 2019
4
HER2 gene (ERBB2) amplification is a low-frequency driver with potential predictive value in gallbladder carcinoma. 61
31838585 2019
5
Prognostic factors and patterns of loco-regional failure in patients with R0 resected gallbladder cancer. 61
31784211 2019
6
AGA Clinical Practice Update on Surveillance for Hepatobiliary Cancers in Patients With Primary Sclerosing Cholangitis: Expert Review. 61
31306801 2019
7
Staging of Biliary and Primary Liver Tumors: Current Recommendations and Workup. 61
31472912 2019
8
Cholecystoduodenal fistula caused by aggressive mucinous gallbladder carcinoma with a porcelain gallbladder. 61
30919282 2019
9
Estimating survival benefit of adjuvant therapy based on a Bayesian network prediction model in curatively resected advanced gallbladder adenocarcinoma. 61
31602165 2019
10
Primary Gallbladder Neuroendocrine Tumors: Insights into a Rare Histology Using a Large National Database. 61
31102094 2019
11
[Large cell neuroendocrine carcinoma with foci of well-differentiated adenocarcinoma of the gallbladder: report of a case]. 61
31495096 2019
12
Intraoperative bile spillage is associated with worse survival in gallbladder adenocarcinoma. 61
31292970 2019
13
18F-FDG PET/CT in detection of occult gallbladder adenocarcinoma presenting as bilateral ovarian Krukenberg tumors. 61
30366729 2019
14
Use of indocyanine green (ICG) augmented near-infrared fluorescence imaging in robotic radical resection of gallbladder adenocarcinomas. 61
31388807 2019
15
Metastatic Gallbladder Adenocarcinoma to the Endometrium: A Case Report and Review of Literature. 61
31572643 2019
16
Albumin In Situ Hybridization Can Be Positive in Adenocarcinomas and Other Tumors From Diverse Sites. 61
31107526 2019
17
Differential diagnosis of focal gallbladder lesions: The added value of contrast enhanced ultrasound with liner transducers. 61
31306115 2019
18
A Case of Acute Pancreatitis Associated with Early-Stage Adenocarcinoma of the Gallbladder. 61
31271565 2019
19
Simultaneous osteosarcoma and adenocarcinoma of the gallbladder: A rare case report and literature review. 61
30460899 2019
20
PIM1 kinase promotes gallbladder cancer cell proliferation via inhibition of proline-rich Akt substrate of 40 kDa (PRAS40). 61
30666556 2019
21
A High Monocyte-to-Lymphocyte Ratio Predicts Poor Prognosis in Patients with Advanced Gallbladder Cancer Receiving Chemotherapy. 61
30842131 2019
22
Uncommon Intraluminal Tumors of the Gallbladder and Biliary Tract: Spectrum of Imaging Appearances. 61
30707646 2019
23
Gallbladder Adenocarcinoma as the First Manifestation of Germline BRCA1 Mutation. 61
28785956 2019
24
Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients. 61
30682533 2019
25
Simple Cholecystectomy Is Adequate for Patients With T1b Gallbladder Adenocarcinoma < 1 cm in Diameter. 61
31192121 2019
26
Challenges and Technical Innovations for an Effective Laparoscopic Lymphadenectomy in Liver Malignancies. 61
30372357 2019
27
[Follicular lymphoma with nodular lesions mimicking gallbladder carcinoma]. 61
31068563 2019
28
Synchronous gallbladder adenocarcinoma and gastric gastrointestinal stromal tumor: Case report and literature review. 61
30818158 2019
29
Dickkopf Homolog 3 (DKK3) Acts as a Potential Tumor Suppressor in Gallbladder Cancer. 61
31737564 2019
30
Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF). 61
29853658 2018
31
[A Resected Case of Gallbladder Cancer Concomitant with Xanthogranulomatous Cholecystitis with Difficulty in Preoperative Diagnosis]. 61
30692481 2018
32
Gallbladder adenocarcinoma diagnosed from cutaneous metastases occurring along the tract of a ventriculoperitoneal shunt. 61
30054926 2018
33
Incidental Gall Bladder Adenocarcinoma in Cholecystectomy Specimens; A Single Center Experience and Review of the Literature. 61
31049173 2018
34
Validation of American Joint Committee on Cancer eighth staging system for gallbladder cancer and its lymphadenectomy guidelines. 61
30100032 2018
35
A predictive model for survival of gallbladder adenocarcinoma. 61
30217289 2018
36
Cytological features of hepatoid adenocarcinoma of the gallbladder: A case report with immunocytochemical analyzes. 61
29637715 2018
37
Classification of gallbladder cancer by assessment of CD8+ TIL and PD-L1 expression. 61
30055582 2018
38
Contrast-enhanced ultrasound findings of gallbladder adenocarcinoma with sarcomatoid carcinoma accompanied by intrahepatic metastasis: A case report and literature review. 61
29794755 2018
39
Concomitant small cell carcinoma and adenocarcinoma of the gallbladder: a case report. 61
29923489 2018
40
Elevated Vitamin B12: A Rare Presentation for Gallbladder Adenocarcinoma. 61
29996035 2018
41
Metastasis of gallbladder adenocarcinoma to the skin of the external auditory canal, a case report. 61
28522135 2018
42
Elevated human chorionic gonadotrophin without pregnancy: A case of gallbladder carcinoma. 61
29292237 2018
43
Expression of vimentin and Oct-4 in gallbladder adenocarcinoma and their relationship with vasculogenic mimicry and their clinical significance. 61
31949742 2018
44
Clinicopathological characteristics and outcomes of rare histologic subtypes of gallbladder cancer over two decades: A population-based study. 61
29889907 2018
45
Tumor Marker Kinetics as Prognosticators in Patients with Unresectable Gallbladder Adenocarcinoma Undergoing Palliative Chemotherapy. 61
29069888 2018
46
[Metastases in trocar sites secondary to gallbladder adenocarcinoma]. 61
30923597 2018
47
[Clinical, epidemiological and therapeutic features of biliary tract cancers: about 20 cases]. 61
29662598 2018
48
Differential diagnostic roles of the serum CA19-9, total bilirubin (TBIL) and the ratio of CA19-9 to TBIL for benign and malignant. 61
29805707 2018
49
Trends of Gallbladder Cancer in Jordan Over 2 Decades: Where Are We? 61
29760576 2018
50
Diabetes and the Pancreatobiliary Diseases. 61
29079901 2017

Variations for Gallbladder Adenocarcinoma

Expression for Gallbladder Adenocarcinoma

Search GEO for disease gene expression data for Gallbladder Adenocarcinoma.

Pathways for Gallbladder Adenocarcinoma

Pathways related to Gallbladder Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 40)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.81 TP53 SRC PIK3CA ERBB2 EGFR
2
Show member pathways
12.65 TP53 SRC PIK3CA ERBB2 EGFR
3
Show member pathways
12.6 TP53 SRC PIK3CA ERBB2 EGFR
4
Show member pathways
12.54 TP53 SRC PIK3CA ERBB2 EGFR
5
Show member pathways
12.48 TP53 SRC PIK3CA ERBB2 EGFR
6 12.47 TP53 PIK3CA ERBB2 EGFR
7
Show member pathways
12.43 TP53 PIK3CA ERBB2 EGFR
8
Show member pathways
12.38 TP53 PIK3CA ERBB2 EGFR
9
Show member pathways
12.33 SRC PIK3CA ERBB2 EPHA7 EGFR
10 12.32 TP53 SRC PIK3CA EGFR
11
Show member pathways
12.3 TP53 SRC PIK3CA ERBB2 EGFR
12
Show member pathways
12.22 SRC PIK3CA ERBB2 EGFR
13
Show member pathways
12.09 TP53 SRC PIK3CA ERBB2 EGFR
14
Show member pathways
12.05 SRC PIK3CA ERBB2 EGFR
15 12.03 SRC ERBB2 EPHA7 EGFR
16 12.03 TP53 SRC PIK3CA ERBB2 EGFR
17
Show member pathways
12 SRC PIK3CA ERBB2 EGFR
18 11.9 PIK3CA ERBB2 EGFR
19
Show member pathways
11.89 PIK3CA ERBB2 EGFR
20 11.86 SRC PIK3CA EGFR
21 11.74 TP53 PEG10 MTDH
22 11.69 TP53 PIK3CA ERBB2
23 11.67 SRC ERBB2 EGFR
24 11.64 SRC ERBB2 EGFR
25 11.62 TP53 PIK3CA ERBB2
26 11.54 SRC ERBB2 EGFR
27 11.47 SRC PIK3CA EGFR
28
Show member pathways
11.47 SRC PIK3CA ERBB2 EGFR
29
Show member pathways
11.45 TP53 SRC PIK3CA ERBB2 EGFR
30 11.42 SRC ERBB2 EGFR
31 11.42 TP53 SRC ERBB2 EGFR
32
Show member pathways
11.38 SRC PIK3CA EGFR
33 11.3 TP53 PIK3CA ERBB2 EGFR
34 11.22 TP53 MTDH EGFR
35 11.16 PIK3CA ERBB2 EGFR
36 11.11 PROM1 ERBB2 EGFR
37 11.01 SRC PIK3CA EGFR
38 10.82 SRC PIK3CA
39 10.82 SRC PIK3CA EGFR
40 10.46 TSG101 SRC PIK3CA EGFR

GO Terms for Gallbladder Adenocarcinoma

Cellular components related to Gallbladder Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 apical plasma membrane GO:0016324 9.02 SLC29A1 PROM1 MTDH ERBB2 EGFR

Biological processes related to Gallbladder Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of protein phosphorylation GO:0001934 9.73 ERP29 ERBB2 EPHA7 EGFR
2 wound healing GO:0042060 9.71 TP53 ERBB2 EGFR
3 positive regulation of MAP kinase activity GO:0043406 9.65 SRC ERBB2 EGFR
4 peptidyl-tyrosine phosphorylation GO:0018108 9.62 SRC ERBB2 EPHA7 EGFR
5 epidermal growth factor receptor signaling pathway GO:0007173 9.58 SRC PIK3CA EGFR
6 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.56 SRC ERBB2 EPHA7 EGFR
7 cellular response to reactive oxygen species GO:0034614 9.54 TP53 SRC EGFR
8 negative regulation of telomerase activity GO:0051974 9.52 TP53 SRC
9 regulation of cell-cell adhesion GO:0022407 9.51 SRC EPHA7
10 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.49 TP53 EGFR
11 negative regulation of ERBB signaling pathway GO:1901185 9.46 ERBB2 EGFR
12 positive regulation of protein kinase B signaling GO:0051897 9.35 SRC PIK3CA MTDH ERBB2 EGFR
13 regulation of ERK1 and ERK2 cascade GO:0070372 9.33 ERBB2 EPHA7 EGFR
14 ERBB2 signaling pathway GO:0038128 8.92 SRC PIK3CA ERBB2 EGFR

Molecular functions related to Gallbladder Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ubiquitin protein ligase binding GO:0031625 9.56 TSG101 TP53 SRC EGFR
2 protein phosphatase binding GO:0019903 9.33 TP53 ERBB2 EGFR
3 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.13 ERBB2 EPHA7 EGFR
4 protein tyrosine kinase activity GO:0004713 8.92 SRC ERBB2 EPHA7 EGFR

Sources for Gallbladder Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....